The future of 23andMe, a genetic testing company, is uncertain due to financial challenges and recent workforce reductions.

In the year since its devastating hack, 23andMe has lost all of its value and most of its governing board — and somehow, ...

Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...

In a significant move to stabilize its operations, 23andMe has announced the layoff of 200 employees, representing a ...

The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the ...

Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...

The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire ...

Me announces 40% workforce reduction and cancellation of therapeutic programs following year of security breaches and ...

We remain deeply grateful to the patients, investigators and study staff for their participation in our clinical trials,” ...

Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to ...

DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as ...

As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.